International Stem Cell Corp. (ISCO) Also Develops Advanced Stem Cell Technology for Skin-Deep Results
A leader in regenerative medicine, International Stem Cell Corp. uses its parthenogenesis stem cell technology to address immune rejection and self-renewing cells. This technology uses unfertilized eggs that have cells with a duplicate set of human leukocyte antigen genes (HLA) that lessen the chance of a body rejecting cells. From this, scientists created self-renewing human parthenogenetic neural stem cells (hpNSC). These cells have the capacity to replace dead and dying neurons while protecting existing ones in patients with Parkinson’s disease. In fact, the company recently presented its preclinical results for the treatment of the disease at Neuroscience in Chicago. Furthermore,…